A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR) (NCT06383273)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300. Researchers will compare MELT-300 to a placebo (a look-alike substance that contains no drug) to see if MELT-300 works on procedural sedation in adult participants undergoing CELR. Researchers will also include a comparator SL midazolam to confirm the benefit of inclusion of ketamine in the combined drug product. The main questions it aims to answer are: 1. Does MELT-300 is effective in comparison to placebo on procedural sedation for cataract surgery? 2. To determine the effectiveness of MELT-300 compared with midazolam on procedural sedation (to determine the contribution of ketamine component and inform the risk of ketamine in MELT-300) 3. To determine the time to achieve preoperative target sedation level with MELT-300 4. What medical problems do participants have when taking MELT-300 vs placebo Eligible participants will admitted to the study unit on Day 1. Participants will be randomized prior to surgery 4:1:1 to 1. MELT-300 (i.e. 1 MELT-300 sublingual tablet which contains 3 mg midazolam and 50 mg of ketamine) 2. Midazolam (i.e. 1 matching midazolam sublingual tablet which contains 3 mg midazolam) 3. Placebo (i.e. 1 matching placebo sublingual tablet) Participants will receive study medication 30 (± 5) minutes, without food or water, before planned surgery start (defined as instillation of topical ocular anesthetic gel \[i.e.. 3 drops of chloroprocaine hydrochloride ophthalmic gel)\]. The effectiveness of MELT-300 will be performed after study medication is administered before surgery, in the course of surgery, and postoperative on Day 1 (end of surgery defined as just prior to drape removal). The safety of MELT-300 will be performed at baseline, in the course of surgery, postoperatively on Day 1, and on Day 3 ± 1 day post dose of study medication.
Who can join: Review the eligibility criteria below.
Location: Ridge Eye Care, Inc. — Chico, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- Ridge Eye Care, Inc. — Chico, California
- Icon Eye Care — Grand Junction, Colorado
- Levenson Eye Associates — Jacksonville, Florida
- Maryland Vision Institute — Hagerstown, Maryland
- Vance Thompson Vision- Alexandria — Alexandria, Minnesota
- Tekwani Vision Center — Bay Saint Louis, Mississippi
- Bergstrom Eye Research — Fargo, North Dakota
- Vance Thompson Vision, ND — West Fargo, North Dakota
- Northeastern Eye Institute — Scranton, Pennsylvania
- Conway Ophthalmology — Conway, South Carolina
- Vance Thompson Vision — Sioux Falls, South Dakota
- Utah Eye Centers- Pleasant Grove — Pleasant Grove, Utah
📞 Contact the Study Coordinator
Phone: (615) 767-0074
Email: gdecastro@meltpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cataract
- Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design — San José,
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution — Glendale, Arizona
- Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement — Babylon, New York
- A Prospective, Single-Arm Clinical Evaluation of Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of the TECNIS PureSee™ Extended Depth of Focus Intraocular Lens — Sioux Falls, South Dakota
- Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+ — Bradenton, Florida
- Visual Outcomes of Tecnis Symfony Opti-Blue EDOF Intraocular Lens (IOL) — Greenwich, Connecticut
Explore by condition: All Cataract clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.